Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables - Net: 2024

Historic Receivables - Net for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2024 value amounting to $8.2 million.

  • ARS Pharmaceuticals' Receivables - Net rose 4615.52% to $36.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.5 million, marking a year-over-year increase of 4615.52%. This contributed to the annual value of $8.2 million for FY2024, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Receivables - Net of $8.2 million as of FY2024.
  • ARS Pharmaceuticals' 5-year Receivables - Net high stood at $8.2 million for FY2024, and its period low was $8.2 million during FY2024.
  • Over the past 1 years, ARS Pharmaceuticals' median Receivables - Net value was $8.2 million (recorded in 2024), while the average stood at $8.2 million.